PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 17, 2026Journal of Intensive Care Medicine0 citations

Specific Therapies For ALF: Viral, Autoimmune and Wilson Disease

View Full Paper
MSMargherita SaraccoSSS. StronaCMChiara Manuli

Key Points

  • The review aims to summarize targeted treatment options for acute liver failure (ALF) related to specific diseases such as autoimmune hepatitis and viral infections.
  • Conducted a structured literature search in PubMed/MEDLINE and Embase
  • Focused on studies published from January 2000 to December 2025
  • Selected original articles, meta-analyses, and clinical guidelines relevant to treatment and outcomes
  • Corticosteroids are first-line treatment for autoimmune hepatitis with a response rate of 70%-80%
  • Early use of nucleos(t)ide analogues improves outcomes in hepatitis B-related ALF
  • Therapeutic plasma exchange may stabilize patients as a bridge to liver transplantation
  • Once severe encephalopathy occurs, specific therapies often become ineffective, necessitating urgent liver transplantation

Abstract

The aim of this review is to provide an updated overview of targeted treatments in ALF due to autoimmune hepatitis, viral infections, and Wilson's disease, emphasizing prognostic assessment and therapeutic decision-making. A structured literature search was performed in PubMed/MEDLINE and Embase for studies published between January 2000 and December 2025 using the terms "acute liver failure," "autoimmune hepatitis," "viral hepatitis," "herpes simplex virus," "Wilson's disease," and "therapeutic plasma exchange." Original articles, meta-analyses, and clinical guidelines in English were selected based on relevance to treatment strategies and outcomes. Acute severe autoimmune hepatitis carries high mortality. Corticosteroids remain first-line therapy, with response rates of 70%-80%. Early identification of non-responders using prognostic models (eg, SURFASA score or composite indices including bilirubin, INR, encephalopathy grade, and platelets) is essential to avoid delaying LT evaluation. Optimal steroid dosing remains debated, as moderate regimens may balance efficacy and infection risk. Viral hepatitis is a major global cause of ALF. In hepatitis B-related ALF or severe reactivation, early nucleos(t)ide analogue therapy improves transplant-free survival. Hepatitis A and E rarely progress to ALF but may cause severe disease in vulnerable individuals. Non-hepatotropic viruses-including HSV, CMV, EBV, VZV, and dengue-can lead to fulminant hepatitis; prompt empirical antivirals, particularly acyclovir for suspected HSV, are critical. Wilson's disease-related ALF is rapidly fatal without LT. Early recognition and validated prognostic indices support urgent transplant referral. Therapeutic plasma exchange may provide temporary stabilization and serve as a bridge to recovery or LT, although high-quality evidence is limited. Once grade 3-4 encephalopathy develops, aetiology-specific therapies often lose effectiveness, and emergency LT-accounting for 2%-8% of annual procedures-remains the only definitive treatment.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Saracco et al. (2026) studied this question.

synapsesocial.com/papers/69e1ce065cdc762e9d8572e8https://doi.org/10.1177/08850666261432156
Ask AI
Helpful
Bookmark
Share
View Full Paper